



Dynavax Schedules Webcast to Report Q4 and YE 2007 Financial Results; Provide 2008 Guidance

BERKELEY, Calif., Feb 15, 2008 (BUSINESS WIRE) -- Dynavax Technologies (Nasdaq:DVAX) will report fourth quarter and year-end 2007 financial results and provide guidance for 2008 on Tuesday, February 19, 2008.

A live webcast will begin at 4:15 p.m. EST (1:15 p.m. PST). The webcast can be accessed from Dynavax's website at www.dynavax.com under the Investors / Events tab or by using the link <http://investors.dynavax.com/events.cfm>.

An archived version of the webcast will be available on the company's website beginning at 7:15 p.m. EST (4:15 p.m. PST) through March 4, 2008.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV(TM), a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBA(TM), a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our hepatitis C therapeutic program, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit <http://www.dynavax.com>.

SOURCE: Dynavax Technologies Corporation

Dynavax Technologies Corporation
Shari Annes, 650-888-0902
Investor Relations
sannes@dynavax.com

Copyright Business Wire 2008

News Provided by COMTEX